The original success of Sildenafil undeniably transformed the drug landscape, but investing in companies heavily reliant on generic versions presents a uncertain picture. While early profits were impressive, the expiration of patents and the emergence of less expensive alternatives have weakened market share. Thus, a thorough analysis of ongoing fi